Allogeneitic CAR-T cell treatment for hematological malignancies

The safety and efficacy of allogeneic CAR-T cells for refractory/relapsed hematological malignancies

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900025431

Enrollment

Unknown

Registered

2019-08-26

Start date

2019-08-23

Completion date

Unknown

Last updated

2019-08-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hematological malignancies

Interventions

CAR-T group:allogeneic CAR-T cell treatment

Eligibility

Sex/Gender

All

Age

No minimum to 70 Years

Inclusion criteria

Inclusion criteria: 1. CD19+ hematological malignancies; 2. ECOG 0-2; 3. Aged 0-70 years.

Exclusion criteria

Exclusion criteria: 1. HIV infection; 2. Active infection; 3. Important organ dysfunction.

Design outcomes

Primary

Measure	Time frame
complete remission rate;the rate of cytokine release syndrome;transfusion associated graft versus host disease;the rate of bone marrow supression;the rate of infection;	—

Countries

China

Contacts

Public ContactHuang He

The First Affiliated Hospital, School of Medicine, Zhejiang University

huanghe@zju.edu.cn+86 13605714822

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026